Medicare AdvantagePrior AuthMedium impact
Levothyroxine Oral Solution (Revised)
Humana·Endocrinology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for levothyroxine oral solution products (Ermeza and Thyquidity) effective January 1, 2026. Members must meet specific criteria for thyroid replacement therapy or thyroid cancer management to receive approval.
Action Required
Before January 1, 2026: Billing team must implement prior authorization requirements for Ermeza and Thyquidity oral solutions for Humana Medicare Advantage patients. Update pharmacy billing system to flag these medications. Providers must document that patient meets criteria for thyroid replacement therapy in primary/secondary/tertiary hypothyroidism OR thyroid cancer management. Claims will be denied without proper prior authorization.